TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure — TRANSFORM-HF  

Heart Failure Clinical Trial

Official title: TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Status Completed

Clinical Trial Summary

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

Clinical Trial Description

- This study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients with heart failure who are hospitalized. Heart failure need not be the reason for hospitalization. Patients will be randomized 1:1 to either oral torsemide OR oral furosemide prior to hospital discharge. Oral dosing of torsemide compared to furosemide will be 1mg:2mg. The specific loop diuretic dose will be at the discretion of the treating physician with the above noted conversion. - Trial enrollment occurs before hospital discharge, at the discretion of the healthcare provider. - As appropriate, adherence to the randomized medication will be encouraged during the remainder of hospitalization and will continue post-discharge. Patients will receive follow-up per standard care without any additional study-specific visits. - Patients will have 30-day, 6-month and 12-month follow-up phone contacts for assessments of vital status, interval hospitalizations, adherence, and quality of life. "Central follow-up" and collection of hospital discharge summaries via IRB-approved mechanisms. Subsets of patients enrolled early in the study have additional phone contacts beyond 12 months, up to 30 months, at six month intervals, to document vital status. ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT03296813
• Study type: Interventional
• Source: Duke University
• Status: Completed
• Phase: Phase 3
• Start date: July 11, 2018
• Completion date: July 29, 2022